Severe Vasculitis Yields to Rituximab (CME/CE)
(MedPage Today) — The B-cell depleting agent rituximab (Rituxan) effectively alleviates serious manifestations of cryoglobulinemic vasculitis, two groups of researchers found.
(MedPage Today) — The B-cell depleting agent rituximab (Rituxan) effectively alleviates serious manifestations of cryoglobulinemic vasculitis, two groups of researchers found.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.